Innovative Microbiome-Based C. difficile Treatments in the Pipeline - Infectious Disease Special Edition
Cationic Homopolymers Inhibit Spore and Vegetative Cell Growth of Clostridioides difficile
A wide range of synthetic polymers have been explored for antimicrobial activity. These materials usually contain both cationic and hydrophobic subunits because these two characteristics are prominent among host-defense peptides. Here, we describe a series of nylon-3 polymers containing only cationi …
Novel Antibiotic for C diff Enters Phase 2 Clinical Trial - Contagionlive.com
Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.
Evogene's Subsidiary Biomica: Impressive Pre-Clinical Data For Its Microbiome Therapeutic BMC128 - Seeking Alpha
Evogene's subsidiary Biomica released impressive pre-clinical data for its clinical candidate BMC128. Read this article to learn more about what this means for the company.
Assessment of Nontraditional Products in Development to Combat Bacterial Infections March 2021 - The Pew Charitable Trusts
While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed. Such nontraditional approaches encompass a variety of products.
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: A phase 1 open-label single-group trial - MD Linx
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1 open-label single-group trial - The Lancet
Destiny Pharma appoints C. difficile expert to its scientific advisory board - Proactive Investors UK
MGB Biopharma - Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3 a Potential New Gold Standard First-Line Treatment for Clostridioides difficile Infection (CDI) - PRNewswire
/PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI),...
Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II - Labiotech.eu
MGB Biopharma's antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after.
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - BioSpace
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).
The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely - Northwest Georgia News
TAMPA, Fla., Jan. 11, 2021 (SEND2PRESS NEWSWIRE) –- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology - Valdosta Daily Times
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 6, 2021--
Destiny Pharma completes enrolment for XF-73 trial on schedule - Proactive Investors UK
XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration
Microbome for c diff works
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections
Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical d...